Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 12,000 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $19.21, for a total value of $230,520.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Chess also recently made the following trade(s):

  • On Monday, August 1st, Robert Chess sold 5,000 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.26, for a total value of $86,300.00.
  • On Friday, July 1st, Robert Chess sold 5,000 shares of Nektar Therapeutics stock. The stock was sold at an average price of $14.10, for a total value of $70,500.00.

Nektar Therapeutics (NASDAQ:NKTR) opened at 19.15 on Thursday. Nektar Therapeutics has a 1-year low of $9.92 and a 1-year high of $19.98. The stock’s 50 day moving average price is $18.10 and its 200 day moving average price is $15.50. The stock’s market capitalization is $2.62 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. Nektar Therapeutics had a negative net margin of 68.30% and a negative return on equity of 8,769.15%. The firm had revenue of $32.77 million for the quarter, compared to the consensus estimate of $34.17 million. During the same period in the previous year, the company posted ($0.40) earnings per share. Nektar Therapeutics’s quarterly revenue was up 44.6% on a year-over-year basis. On average, equities research analysts predict that Nektar Therapeutics will post ($1.11) earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in NKTR. Mason Street Advisors LLC purchased a new position in shares of Nektar Therapeutics during the second quarter worth approximately $379,000. Schwab Charles Investment Management Inc. raised its position in shares of Nektar Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 466,288 shares of the biopharmaceutical company’s stock worth $6,636,000 after buying an additional 8,280 shares during the last quarter. Amalgamated Bank raised its position in shares of Nektar Therapeutics by 8.5% in the second quarter. Amalgamated Bank now owns 15,020 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 1,177 shares during the last quarter. Legal & General Group Plc raised its position in shares of Nektar Therapeutics by 15.6% in the second quarter. Legal & General Group Plc now owns 33,763 shares of the biopharmaceutical company’s stock worth $472,000 after buying an additional 4,553 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of Nektar Therapeutics by 1.6% in the second quarter. Arizona State Retirement System now owns 70,745 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 1,100 shares during the last quarter. 96.91% of the stock is owned by institutional investors.

A number of brokerages have commented on NKTR. Jefferies Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research note on Thursday, September 8th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Piper Jaffray Cos. reissued an “overweight” rating and set a $21.00 target price (up from $17.00) on shares of Nektar Therapeutics in a research note on Friday, August 5th. Finally, Brean Capital reissued a “buy” rating and set a $18.00 target price on shares of Nektar Therapeutics in a research note on Friday, August 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $19.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.